Stockwatch: Lonely product seeks patients to recover costs of development
This article was originally published in Scrip
Executive Summary
One of the consequences of the sequencing of the human genome in 2000 is the large number of biotechnology companies developing new drugs. Theoretically, at some point the number of companies will exceed the number of possible indications in human disease. But before we get to that stage, there are already quite a few of drugs that have been approved for such small indications that their costs of development can never be recovered.